Interesting data from their 2020 990 filing

The purpose of the non-profit, as set forth in the filing, is “The mission of dndi north america is to contribute to the achievement of dndi's global objectives, in particular to strenghten and expand dndi's scientific, policy advocacy, fundraising, and communications efforts in north america by (a) providing focused support for specific r&d projects and business/partner development activities in north america;(b) achieving concrete policy changes in north america to create a more favorable environment for needs-driven r&d for neglected diseases;(c) mobilizing public and private funds in north america to support dndi's mission;(d) increasing dndi's profile and visibility in north america, thereby drawing greater public attention to the need for neglected disease r&d.”.

When discussing its purpose, they were characterized as: “The drugs for neglected diseases initiative (dndi), north america supports dndi's global vision and mission to develop new drugs, or new formulations of existing drugs for patients suffering from the most neglected diseases. acting in the public interest, dndi bridges existing r&d gaps in essential drugs for these diseases by initiating and coordinating drug r&d projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other partners.”.

• The state in which the non-profit is legally authorized to operate is DE, as reported.
• The filing confirms that the non-profit's address in 2020 was 40 RECTOR STREET 16TH FLOOR, NEW YORK, NY, 10006.
• The form of the non-profit reports 12 employees as of 2020.
• Is not a private foundation.
• Expenses are greater than $1,000,000.
• Revenue is greater than $1,000,000.
• Revenue less expenses is $33,737.
• The organization has 7 independent voting members.
• The organization was formed in 2007.
• The organization pays $1,518,437 in salary, compensation, and benefits to its employees.
• The organization pays $779,806 in fundraising expenses.